ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/CTLA4
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/CTLA4
25
trial(s) found.
NCT06792695
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (
CANTOR
)
Bevacizumab
Fluorouracil
Irinotecan
Leucovorin
Volrustomig
anti-VEGF monoclonal antibody
antimetabolite
bispecific PD-L1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,VEGF-targeting
therapeutic modality,bispecific antibody
topoisomerase inhibitor
+ bispecific PD-L1/CTLA4 antibody
Colorectal cancer
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06097728
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (
eVOLVE-Meso
)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
antimetabolite
bispecific PD-L1/CTLA4 antibody
platinum-based antineoplastic agent
Pleural mesothelioma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05987332
Advanced
Phase 2 / Phase 3
Recruiting
IDE196 (Darovasertib) in Combination with Crizotinib Versus Investigator's Choice of Treatment As First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2) (
IDE196-002
)
ALK inhibitor,first generation
MET inhibitor,type 1
PKC inhibitor
ROS1 inhibitor
+ cancer therapy,CTLA4-targeting
Uveal melanoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3181 - Prahran - The Alfred Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05984277
Advanced
Phase 3
Recruiting
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC). (
eVOLVE-Lung02
)
anti-PD-1 monoclonal antibody
bispecific PD-L1/CTLA4 antibody
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT05671510
Advanced
Phase 3
Recruiting
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors (
PRESERVE-003
)
anti-CTLA-4 monoclonal antibody
taxane
+ cancer therapy,CTLA4-targeting
Non-small cell lung cancer
NSW
2200 - Bankstown - Bankstown-Lidcombe Hospital
2305 - New Lambton Heights - Newcastle Private Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05180799
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors (
BA3071-001
)
anti-CTLA-4 monoclonal antibody
+ cancer therapy,CTLA4-targeting
Melanoma
Non-small cell lung cancer
NSW
2228 - Miranda - Southside Cancer Care Centre
2640 - Albury - Albury Wodonga Regional Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT04938817
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98) (
3475-B98
)
anti-PD-1 monoclonal antibody
+ cancer therapy,CTLA4-targeting
Small-cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (COMPLETED)
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital (COMPLETED)
WA
6009 - Nedlands - Hollywood Private Hospital
NCT04686305
Advanced
Phase 1
Recruiting
A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03) (
DL03
)
anti-ERBB2 antibody-drug conjugate
+ bispecific PD-L1/CTLA4 antibody
Non-small cell lung cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (WITHDRAWN)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04665206
Advanced
Phase 1
Recruiting
Phase 1, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients with Refractory Locally Advanced or Metastatic Solid Tumors (
VT3989-001
)
TEAD palmitoylation inhibitor
+ cancer therapy,CTLA4-targeting
Mesothelioma
Non-small cell lung cancer
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT04612751
Advanced
Phase 1
Recruiting
A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (
Tropion-Lung04
)
anti-Trop2 antibody-drug conjugate
platinum-based antineoplastic agent
+ bispecific PD-L1/CTLA4 antibody
Non-small cell lung cancer
NCT04524871
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (
Morpheus-Liver
)
ADG126
Atezolizumab
Bevacizumab
HIF2a inhibitor
NKT2152
PPAR-alpha inhibitor
TPST-1120
Tiragolumab
Tobemstomig
Tocilizumab
anti-CTLA-4 monoclonal antibody
anti-IL-6 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,HIF2a-targeting
cancer therapy,IL-6-targeting
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PPAR-alpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
+ cancer therapy,CTLA4-targeting
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04305054
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B (
3475-02B
)
anti-PD-1 monoclonal antibody
+ cancer therapy,CTLA4-targeting
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
QLD
4215 - Southport - Tasman Oncology (COMPLETED)
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT04140526
Advanced
Phase 1 / Phase 2
Recruiting
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (
PRESERVE-001
)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
+ cancer therapy,CTLA4-targeting
Adenoid cystic carcinoma
Breast cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck cancer
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Salivary gland cancer
Sarcoma
Small-cell lung cancer
Solid tumour
Urothelial carcinoma
NSW
2305 - New Lambton Heights - Newcastle Private Hospital
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
ACTRN12623000096651
Advanced
Phase 2
Recruiting
LUMOS2
: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS
Cadonilimab
Niraparib
PARP inhibitor
PI3K-delta inhibitor
PI3K alpha inhibitor
PI3K inhibitor
Paxalisib
Selinexor
XPO1 inhibitor
bispecific PD-1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PARP-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PI3K-delta-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,XPO1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
dual PI3K/mTOR inhibitor
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-1-targeting
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
therapeutic modality,bispecific antibody
+ bispecific PD-1/CTLA4 antibody
Anaplastic astrocytoma
Low-grade glioma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12621001155886
Advanced
Phase 1 / Phase 2
Recruiting
Phase Ib/II study of safety and clinical response to Azacitidine and Carboplatin priming for Ipilimumab and Nivolumab re-challenge in patients with advanced melanoma who are resistant to immunotherapy. (
PRIME005
)
DNA methyltransferase inhibitor
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
antimetabolite
platinum-based antineoplastic agent
+ cancer therapy,CTLA4-targeting
Melanoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
QLD
4870 - Cairns - Cairns Base Hospital
ACTRN12621000156886
Advanced
Phase 1 / Phase 2
Recruiting
A pilot study of Perindopril in combination with first line Ipilimumab and Nivolumab for patients with unresectable or metastatic melanoma- ACE-IT 001 (
ACE-IT001
)
ACE inhibitor
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
+ cancer therapy,CTLA4-targeting
Melanoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
NCT05858736
Advanced
Phase 1
Active not recruiting
Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study (
PRESERVE-009
)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
+ cancer therapy,CTLA4-targeting
Adenocarcinoma
Anal cancer
Biliary tract cancer
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Fallopian tube cancer
Gastric cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Primary peritoneal serous carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05848011
Advanced
Phase 2
Active not recruiting
A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer (
CP-MGD019-02
)
bispecific PD-1×CTLA-4 dual-affinity responsive target molecule
taxane
+ bispecific PD-L1/CTLA4 antibody
Prostate cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT05505825
Advanced
Phase 1 / Phase 2
Completed
A Phase Ib/II Clinical Study of Anti-PD-1 and CTLA-4 Bispecific Antibody, Cadonilimab(AK104), in Combination With Chiauranib in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer Who Failed First-line Platinum-based Chemotherapy in Combination With Programmed Cell Death-1(PD1)/Programmed Cell Death Protein Ligand-1(PDL1) Inhibitors (
AK104-212
)
bispecific PD-1/CTLA4 antibody
Small-cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT05212922
Advanced
Phase 2
Withdrawn
An Open-Label, Non-Randomized, Multi-center Phase 2 Study of
YH001
in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) and Hepatocellular Carcinoma (HCC)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
+ cancer therapy,CTLA4-targeting
Hepatocellular carcinoma
Non-small cell lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
NCT05116202
Advanced
Phase 1 / Phase 2
*paused
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) (
BO43328
)
Atezolizumab
Ipilimumab
Nivolumab
RO7247669
Tiragolumab
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,TIGIT-targeting
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
+ cancer therapy,CTLA4-targeting
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT03994393
Advanced
Phase 2
Unknown
A Phase 2 Trial of Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy in Metastatic EGFR Mutant Non-squamous Non-small Cell Lung Cancer (NSCLC) Following Progression on EGFR Tyrosine Kinase Inhibitors (TKIs) (
ILLUMINATE
)
anti-CTLA-4 monoclonal antibody
anti-PD-L1 monoclonal antibody
+ cancer therapy,CTLA4-targeting
EGFR-mutant non-small cell lung cancer
Non-small cell lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT03529526
Advanced
Phase 1
Status unknown
An Open-Label, Multi-center, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of KN046 in Subjects With Advanced Solid Tumors (
KN046-AUS-001
)
bispecific PD-L1/CTLA4 antibody
Solid tumour
QLD
4215 - Southport - ICON Cancer Care
NCT03261011
Advanced
Phase 1
Status unknown
A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors (
AK104-101
)
bispecific PD-1/CTLA4 antibody
Cancer
NA
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT03177239
Advanced
Phase 2
Status unknown
A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602). (
UNISoN
)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
+ cancer therapy,CTLA4-targeting
Carcinoma
Chromophobe renal cell carcinoma
Clear cell renal cell carcinoma
Sarcomatoid renal cell carcinoma
Type 1 papillary renal cell carcinoma
Type 2 papillary renal cell carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2086 - Frenchs Forest - Northern Beaches Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (16)
Status unknown (3)
Active not recruiting (2)
Completed (1)
Withdrawn (1)
*paused (1)
Unknown (1)
Recruitment Country and State
NSW (20)
QLD (15)
VIC (14)
SA (10)
WA (9)
TAS (2)
NZ (1)
Phase
Phase 1 (6)
Phase 1 / Phase 2 (9)
Phase 2 (6)
Phase 2 / Phase 3 (1)
Phase 3 (3)
Trial Type
Advanced (25)
Cancer Therapy Class
CTLA4
100%
PD-1/PD-L1
96%
PD-1
80%
PD-L1
40%
TIGIT
20%
VEGF
16%
LAG3
16%
ALK
4%
MET
4%
PKC
4%
ROS1
4%
ILT4
4%
ERBB2
4%
EGFR
4%
YAP-TEAD
4%
TIM3
4%
Trop2
4%
HIF2a
4%
IL-6
4%
PPAR-alpha
4%
PARP
4%
PI3K-delta
4%
PI3K
4%
PI3Kalpha
4%
XPO1
4%
mTOR
4%
mTORC1
4%
mTORC2
4%
DNA methyltransferase
4%
ACE
4%
Facility
3168 - Clayton - Monash Medical Centre (8)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (7)
3000 - Melbourne - Peter MacCallum Cancer Centre (5)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (5)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (5)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (4)
4102 - Woolloongabba - Princess Alexandra Hospital (4)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (4)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (4)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (4)
5042 - Bedford Park - Flinders Medical Centre (4)
4032 - Chermside - The Prince Charles Hospital (3)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
4215 - Southport - Tasman Oncology (3)
2170 - Liverpool - Liverpool Hospital (3)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
2305 - New Lambton Heights - Newcastle Private Hospital (2)
2640 - Albury - Albury Wodonga Regional Cancer Centre (2)
6009 - Nedlands - Linear Clinical Research (2)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (2)
7000 - Hobart - Royal Hobart Hospital (2)
2217 - Kogarah - St George Hospital (2)
2500 - Wollongong - Wollongong Hospital (1)
3002 - East Melbourne - Epworth Freemasons (1)
3181 - Prahran - The Alfred Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
2228 - Miranda - Southside Cancer Care Centre (1)
6009 - Nedlands - Hollywood Private Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
3066 - Epping - Northern Hospital (1)
4870 - Cairns - Cairns Base Hospital (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4215 - Southport - ICON Cancer Care (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
2031 - Randwick - Prince of Wales Hospital (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
Cancer Type
Cancer
Solid tumour
Thoracic cancer
Lung cancer
Respiratory tract cancer
Non-small cell lung cancer
Melanoma
Gastrointestinal cancer
Carcinoma
Upper gastrointestinal cancer
Urogenital cancer
Colorectal cancer
Lower gastrointestinal cancer
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Hepatobiliary cancer
Hepatocellular carcinoma
Clear cell renal cell carcinoma
Kidney cancer
Mesothelioma
Cervical cancer
Gastric cancer
Gastroesophageal cancer
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Head and neck cancer
Male genital cancers
Oesophageal cancer
Pancreatobiliary cancer
Prostate cancer
Viral-related cancer
Pleural mesothelioma
Uveal melanoma
Adenoid cystic carcinoma
Breast cancer
Cancer Solid tumour Carcinoma
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Ovarian cancer
Pancreatic cancer
Salivary gland cancer
Sarcoma
Urothelial carcinoma
Anaplastic astrocytoma
Central nervous system cancer
Glioma
High-grade glioma
Low-grade glioma
Malignant glioma
Neurological cancer
Adenocarcinoma
Anal cancer
Biliary tract cancer
Bladder cancer
Endometrial cancer
Fallopian tube cancer
Head and neck squamous cell carcinoma
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Peritoneal cancer
Primary peritoneal serous carcinoma
EGFR-mutant non-small cell lung cancer
Chromophobe renal cell carcinoma
Non-clear cell renal cell carcinoma
Papillary renal cell carcinoma
Sarcomatoid renal cell carcinoma
Type 1 papillary renal cell carcinoma
Type 2 papillary renal cell carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy